Nymox Pharmaceutical Corporation NYMX is pleased to announce the first patient enrolment for Study NX03-0040, the Company's Phase 2 Study of NX-1207 for low risk localized prostate cancer. NX-1207 is also in Phase 3 development in the U.S. and Europe for benign prostatic hyperplasia (BPH).
Preclinical studies of NX-1207 have shown activity against prostate cancer cells at higher dosage levels of NX-1207 than the dosage used in the current Phase 3 BPH clinical trials. The new study will test both low and high doses of NX-1207 for their effect on low grade localized prostate cancer. Efficacy in the study will be assessed 6 weeks after NX-1207 treatment.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in